ALVYQO H1 – PUBLIC TECHNICAL OVERVIEW
Development-stage modular measurement system – not for clinical use
Version: WEB-PUBLIC v1.1
Release class: PUBLIC / NON-CONFIDENTIAL
Language: English
1. Purpose of this document
ALVYQO H1 is a development-stage project for a modular measurement system. This public technical overview describes the high-level engineering structure and development principles without disclosing confidential implementation details.
This document is not a product specification, manufacturing drawing, clinical performance report or regulatory approval.
2. High-level system architecture
Common terminal: user operation, measurement-process control, state handling and result presentation are implemented within a shared device environment.
Interchangeable test units: the modular architecture is intended to allow appropriately matched test units for different measurement tasks to connect to the same base platform.
Firmware and software: control, structured data handling, auditability and later external connectivity are based on controlled interfaces.
This document does not lock the exact assay portfolio, final intended purposes, test menu or performance values.
3. Engineering development principles
Modular and unambiguous interfaces, with controlled separation of mechanical, electronic and software development.
Verification based on measurable and predefined acceptance criteria.
Reproducible and traceable measurement and state-management logic; primary result handling must be capable of validation.
Preference for commercially obtainable components where technically and qualitatively appropriate.
Information security, access control and data protection treated as system requirements.
4. Current development status
The project is currently in development, prototype and engineering-verification stages. Analytical or clinical performance of the proprietary system is not presented in this document as established evidence.
The project is not represented as a CE-marked, clinically validated or market-ready diagnostic product. Final intended purpose, regulatory pathway and performance requirements can be locked only on the basis of sufficient technical and regulatory evidence.
5. What is not included in this public overview?
Detailed schematics, PCB layouts, the complete BOM, calibration models, algorithms, source code, firmware details, manufacturing files, exact internal geometry, unpublished test evidence and security-sensitive implementation details are outside the scope of this document.
6. Collaboration
Public information may be used for initial technical orientation. If more detailed collaboration with a potential partner is justified, further material may be disclosed only under an appropriate confidentiality framework, access and need-to-know controls, and separate approval by the project owner.
© Ferenc Jeney · ALVYQO · Development documentation
ALVYQO H1 – PRE-NDA PARTNER PROJECT SUMMARY
Non-confidential document for initial external contact
Version: PRE-NDA v1.2
Release class: NON-CONFIDENTIAL / INITIAL EXTERNAL CONTACT
Language: English
1. Purpose
This document is intended to help a potential development, manufacturing, technology or strategic partner understand the nature of the ALVYQO H1 project, its current development stage and the principles of controlled collaboration. It may be used for initial contact without disclosing confidential technical material.
2. Project in brief
ALVYQO H1 is a development-stage project for a modular measurement system. The system is built around a common terminal and software environment together with interchangeable test units matched to the relevant measurement task.
Current work focuses on coordinated development of mechanics, electronics, firmware, software, measurement chains, prototypes and documented engineering verification.
3. What kind of collaboration are we seeking?
Relevant competence may include medical-device/IVD engineering, analog and digital electronics, embedded firmware, software, sensor and measurement technology, mechanical and prototype development, manufacturing preparation, testing, quality management, regulatory support and other related expertise.
The actual partner scope is always defined separately; a complete development quotation is not automatically requested during first contact.
4. What may be shared at PRE-NDA level?
The high-level project objective and development status; non-confidential descriptions of the main system blocks; the competences being sought; the general framework for the next engineering work stages; and the controlled process for moving forward.
5. What is not shared before NDA?
Detailed schematics, PCB layouts, the complete BOM, source code, firmware or algorithm details, calibration models, exact internal geometry, manufacturing files, unpublished test evidence, patent-sensitive material, partner quotations and internal cost information are not disclosed before an appropriate confidentiality framework is in place.
The project maintains detailed, version-controlled technical documentation covering areas including system architecture, Reader electronics, test cartridge and microfluidics, firmware and software, prototype and bench evidence, verification, and risk management.
A signed NDA + non-circumvention agreement is required, but it does not by itself create automatic access. The project owner separately evaluates the seriousness and relevance of the enquiry and the partner's actual scope; after approval, only the latest reviewed or separately release-approved documents needed for the assigned task may be disclosed on a need-to-know basis with logged, time-limited and revocable access.
6. Planned partner process
1) Initial non-confidential contact and competence feedback.
2) Preliminary definition of the possible collaboration area.
3) Where appropriate, acceptance of a suitable confidentiality and non-circumvention framework.
4) Separate project-owner approval and access rights tied to a partner account.
5) Controlled disclosure only of detailed documents required for the assigned task.
6) Definition of RFQ/SOW, deliverables, acceptance criteria and schedule based on the concrete scope.
7. Important status boundary
ALVYQO H1 is a development project. This document does not claim clinical validation, CE marking, established proprietary analytical performance, patentability, FTO, final manufacturing cost, final market price or committed funding.
Detailed confidential project material may be disclosed only for a justified partner purpose, under an appropriate contractual framework, on a need-to-know basis and with separately approved access.
© Ferenc Jeney · ALVYQO · Development documentation